Haemophilia

The following areas of research are currently among those being considered to support novel, independent research that advances general knowledge for Sobi’s products within Haemophilia.

Preclinical and basic science studies

  • Biomarkers and novel assessments of microbleeding, bleed resolution, inflammation and joint damage
  • Studies on immunogenicity and induction of immune tolerance
  • Predictive genetic and proteomic markers for haemophilia treatment outcome

Clinical studies

  • Biomarkers and novel assessments of microbleeding, bleed resolution, inflammation and joint damage
  • Studies on immunogenicity and induction of immune tolerance
  • Joint health and dysfunction
  • Outcomes related to comorbidities of aging haemophilia population e.g., cardiovascular, diabetes mellitus, cancer

Patient, caregiver and health economic studies

  • Such as Quality of Life, psychosocial function, pain, work productivity, pharmacoeconomics, and health resource utilisation

Inflammation

The following areas of research are currently among those being considered to support novel, independent research that advances general knowledge for Sobi’s product in Inflammation, anakinra.

Clinical studies

  • Clinical outcomes in IL-1 autoinflammatory diseases
  • Clinical outcomes and predictors of response (e.g., biomarkers, patient characteristics) to anakinra therapy in rheumatoid arthritis
  • Proof of concept and efficacy studies for the role of anakinra to affect clinical outcomes in IL-1 driven diseases. These diseases must be well-characterized and have strong evidence for the role of IL-1 in their pathophysiology.